Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novo Nordisk
Novo Nordisk
Finding the big spenders beyond big pharma
EP Vantage
Mon, 04/24/23 - 10:15 am
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
What spurred Lilly, Novo and Sanofi to slash insulin prices? Expert gives her take
Fierce Pharma
Fri, 04/21/23 - 10:22 am
Novo Nordisk
Eli Lilly
Sanofi
insulin
diabetes
drug prices
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
With Wegovy supply unfettered, Novo Nordisk ratchets up its 2023 growth forecast
Fierce Pharma
Fri, 04/14/23 - 10:29 am
Novo Nordisk
Wegovy
Novo’s latest deal targets cell therapy for diabetes, obesity
BioPharma Dive
Thu, 04/13/23 - 12:02 pm
Novo Nordisk
cell therapy
diabetes
obesity
Aspect Biosystems
Bernie Sanders weighs Senate hearing for largest insulin makers
Seeking Alpha
Thu, 04/13/23 - 11:53 am
Bernie Sanders
diabetes
insulin
drug pricing
Eli Lilly
Sanofi
Novo Nordisk
Senate
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
Motley Fool
Thu, 04/6/23 - 11:29 am
Novo Nordisk
diabetes
Ozempic
Rybelsus
Biopharma stocks go back to bleak
EP Vantage
Thu, 04/6/23 - 09:51 am
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
Diabesity drugs and their free ‘contract sales force’
Medical Marketing and Media
Tue, 04/4/23 - 10:12 am
Novo Nordisk
Eli Lilly
diabetes
obesity
telehealth
social media
Mounjaro
Wegovy
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CP Wire
Mon, 04/3/23 - 03:35 pm
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
Mon, 04/3/23 - 03:33 pm
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
CHMP gives thumbs-up for Wegovy use in adolescents, along with nine new drug recommendations
Endpoints
Sun, 04/2/23 - 04:17 pm
EMA
Europe
CHMP
Wegovy
Novo Nordisk
Bimervax
TG Therapeutics
Eli Lilly
Bristol Myers Squibb
Novartis
AstraZeneca
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries
Fierce Pharma
Mon, 03/27/23 - 11:23 am
Novo Nordisk
Rybelsus
diabetes
clinical trials
Eli Lilly
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
Investors Business Daily
Sun, 03/26/23 - 11:28 pm
Novo Nordisk
Ozempic
diabetes
obesity
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
Sun, 03/26/23 - 03:44 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Sun, 03/26/23 - 03:36 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline
Enpoints
Wed, 03/22/23 - 11:13 am
Dewpoint Therapeutics
Novo Nordisk
diabetes
insulin resistance
condensates
Six-month Ozempic shortage mostly over after weight-loss craze drained supply
Seattle Times, WA
Mon, 03/20/23 - 04:39 pm
Novo Nordisk
drug shortages
Ozempic
diabetes
weight loss
Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Endpoints
Thu, 03/16/23 - 09:16 pm
Sanofi
Lantus
insulin
diabetes
drug pricing
Eli Lilly
Novo Nordisk
Pages
« first
‹ previous
…
8
9
10
11
12
13
14
15
16
…
next ›
last »